Alice T. Shaw
Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.
Overview
Alice Shaw led the clinical development of ALK and ROS1 inhibitors while at Massachusetts General Hospital. She was first author of the 2014 New England Journal of Medicine report showing crizotinib's activity in ROS1-rearranged non-small-cell lung cancer, which led to its approval for that indication, and led trials of ceritinib, alectinib and lorlatinib and studies of ALK resistance mutations. In 2019 she moved to Novartis to lead translational clinical oncology.
Similar pages
not linked directly; found by shared links- PersonGregory J. Riely
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonKeunchil Park
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonPaul K. Paik
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonRobert C. Doebele
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonMatthew D. Hellmann
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonD. Ross Camidge
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonFerdinandos Skoulidis
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonMartin Reck
Shares Non-small-cell lung cancer and the tags lung, trialist.